The value of laboratory indicators estimation in patients with metabolically healthy obesity: analysis of a clinical case with literature review
Abstract
Introduction. Obesity currently is a relevant issue of modern medicine due to its global prevalence, heterogeneity of clinical and laboratory manifestations, as well as the association with various comorbid conditions. Depending on the metabolic status, metabolically unhealthy obesity (MUO) and metabolically healthy obesity (MHO) are distinguished. MUO is defined with the presence of criteria for metabolic syndrome (MS) and is associated with an increased risk of cardiovascular and metabolic complications. MHO is characterized by a «metabolically healthy» profile, but the probability of a favorable course of the disease is controversial; many studies indicate the instability of the MHO phenotype and the possibility of further development of MUO. The aim of study: to analyze the features of laboratory indicators associated with MHO and determine the risk factors for the MUO development on the example of a clinical case. Materials and methods. A clinical case of 24 year old female patient diagnosed with alimentary-constitutional obesity class III. Objectively: height – 174 cm, weight – 124.7 kg, body mass index (BMI) – 41.21 kg/m2, waist circumference – 107 cm, hips circumference – 144 cm; white striae on the abdomen; excessive subcutaneous fat stores, mostly distributed in the abdomen, thighs; blood pressure (BP) – 125/80 mm Hg. Investigation data: hyperleptinemia – 86.82 ng/ml, increased level of HOMA index – 4.6, hyperuricemia – 6.8 mg/dl, vitamin D deficiency – 9.19 ng/ml; lipid profile, fasting plasma glucose, glycated haemoglobin (HbA1c), thyroid stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4), anti-thyroid peroxidase (anti-TPO) antibodies, cortisol, blood electrolytes, liver function tests – within normal limits. Electrocardiography (ECG), ultrasound of the heart and abdominal organs – without pathology. Results. Normal indicators of lipid metabolism, blood glucose and BP measurement in our patient are characteristic for MHO. However, the combination of hyperleptinemia with insulin resistance, hyperuricemia and vitamin D3 deficiency indicate metabolic and hormonal imbalance and are considered as a risk factors for the development of MS and the further transition of MHO to MUO. Conclusion. MHO should be considered as a transient state, the management of such patients requires careful laboratory monitoring with early detection of metabolic disorders and its adequate and timely correction.
Downloads
References
WHO. Obesity and overweight [document on the Internet]. World Health Organisation; 2021 [cited 2021 September 15]. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/
Fadeenko GD, Maslyaeva LV. Ozhirenie kak problema klinicheskoy meditsinyi. Liky Ukrainy. 2009; 6 (132): 31–7 [In Russian].
Doslidzhennia STEPS: poshyrenist faktoriv ryzyku neinfektsiinykh zakhvoriuvan v Ukraini u 2019 rotsi. Kopenhahen, Yevropeiske rehionalne biuro VOOZ. 2020. [In Ukrainian] Available from: https://apps.who.int/iris/bitstream/handle/10665/336643/WHO-EURO-2020-1468-41218-56061-ukr.pdf
Durrer Schutz D, Busetto L, Dicker D, Farpour-Lambert N, et al. European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obes Facts 2019; 12: 40–66. DOI: https://doi.org/10.1159/000496183
Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016; 22 (3): 1–203. DOI: https://doi.org/10.4158/EP161365.GL
Purnell JQ. Definitions, Classification, and Epidemiology of Obesity. In: Feingold KR, Anawalt B,
Boyce A, et al., editors. Endotext [Internet]. 2018 [cited 2021 Sep 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279167/
Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013; 309 (1): 71–82. DOI: https://doi.org/10.1001/jama.2012.113905
Romantsova TI, Ostrovskaya EV, Metabolicheski zdorovoe ozhirenie: definitsii, protektivnyie faktoryi, klinicheskaya znachimost. Almanah klinicheskoy meditsinyi [serial online]. 2015. 13 (21): 75–87. [In Russian] Available from: https://www.almclinmed.ru/jour/article/view/73/74
Alberti KG, Eckel RH, Grundy SM, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International
Association for the Study of Obesity. Circulation. 2009; 120 (16): 1640–5. DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.192644
Muñoz-Garach A, Cornejo-Pareja I, Tinahones FJ. Does Metabolically Healthy Obesity Exist? Nutrients. 2016; 8 (6): 320. DOI: https://doi.org/10.3390/nu8060320
Brandão I, Martins MJ, Monteiro R. Metabolically Healthy Obesity-Heterogeneity in Definitions and Unconventional Factors. Metabolites. 2020; 10 (2): 48. DOI: https://doi.org/10.3390/metabo10020048
van Vliet-Ostaptchouk JV, Nuotio M-L, Slagter SN, et al.The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocrine Disorders. 2014; 14 (1): 9. DOI: https://doi.org/10.1186/1472-6823-14-9
Jung CH, Lee WJ, Song KH. Metabolically healthy obesity: a friend or foe? Korean J Intern Med. 2017; 32 (4): 611–621. DOI: https://doi.org/10.3904/kjim.2016.259
Karelis AD, Rabasa-Lhoret R. Obesity: Can inflammatory status define metabolic health? Nat Rev Endocrinol. 2013 Dec; 9 (12): 694–5. DOI: https://doi.org/10.1038/nrendo.2013.198
Esteghamati A, Aryan Z, Esteghamati A, Nakhjavani M. Differences in vitamin D concentration between metabolically healthy and unhealthy obese adults: associations with inflammatory and
cardiometabolic markers in 4391 subjects. Diabetes Metab. 2014; 40 (5): 347–55. DOI: https://doi.org/10.1016/j.diabet.2014.02.007
Tremmel M, Lyssenko V, Zöller B et al. Characteristics and prognosis of healthy severe obesity
(HSO) subjects – The Malmo Preventive Project. Obesity Medicine. 2018; 11: 6–12. DOI: https://doi.org/10.1016/j.obmed.2018.06.005
Soriguer F, Gutiérrez-Repiso C, Rubio-Martín E, et al. Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. J Clin Endocrinol Metab. 2013; 98 (6): 2318–25. DOI: https://doi.org/10.1210/jc.2012-4253
Hwang YC, Hayashi T, Fujimoto WY, et al. Visceral abdominal fat accumulation predicts the conversion of metabolically healthy obese subjects to an unhealthy phenotype. Int J Obes 2015; 39: 1365–1370. DOI: https://doi.org/10.1038/ijo.2015.75
Schröder H, Ramos R, Baena-Díez JM, Mendez MA, Canal DJ, Fíto M, Sala J, Elosua R. Determinants of the transition from a cardiometabolic normal to abnormal overweight/obese phenotype in a Spanish population. Eur J Nutr. 2014; 53 (6): 1345–53. DOI: https://doi.org/10.1007/s00394-013-0635-2
Uchamprina VA., Romantsova TI. Kalashnikova MF. Metabolicheskiy sindrom: argumentyi
«za» i «protiv». Ozhirenie i metabolizm. 2012; (9) 2: 17–27. [In Russian] DOI: https://doi.org/10.14341/omet2012217-27
Zagayko A L., Bryuhanova TA., Shkapo AI. Giperurikemiya kak element patogeneza metabolicheskogo sindroma. Ukrainian biopharmaceutical journal. 2015; 1 (36): 47–51. [In Russian] Available from: http://nbuv.gov.ua/UJRN/ubfj_2015_1_12
Gruzdeva O, Borodkina D, Uchasova E, Dyleva Y, Barbarash O. Leptin resistance: underlying mechanisms and diagnosis. Diabetes Metab Syndr Obes. 2019; 12:191-198. DOI: https://doi.org/10.2147/DMSO.S182406
Osegbe I, Okpara H, Azinge E. Relationship between serum leptin and insulin resistance among obese Nigerian women. AnnAfrMed. 2016; 15 (1): 14–19. DOI: https://doi.org/10.4103/1596-3519.158524
Ghantous CM, Azrak Z, Hanache S, Abou-Kheir W, Zeidan A. Differential Role of Leptin and Adiponectin in Cardiovascular System. Int J Endocrinol. 2015; 2015: 534320. DOI: https://doi.org/10.1155/2015/534320
Jamar G, Caranti DA, de Cassia Cesar H, Masquio DCL, Bandoni DH, Pisani LP. Leptin as a cardiovascular risk marker in metabolically healthy obese: Hyperleptinemia in metabolically healthy obese. Appetite. 2017; 108: 477–482. DOI: https://doi.org/10.1016/j.appet.2016.11.013
Duque AP, Rodrigues Junior LF, Mediano MFF, Tibiriça E, De Lorenzo A. Emerging concepts in metabolically healthy obesity. Am J Cardiovasc Dis. 2020; 10 (2): 48–61. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364278/
ChangCS, LuYJ, ChangHH et al. Role of adiponectin gene variants, adipokines and hydrometry-based percent body fat in metabolically healthy and abnormal obesity. Obes Res ClinPract. 2018; 12 (2): 49–61. DOI: https://doi.org/10.1016/j.orcp.2016.05.003
Zak KP, Mankovskiy BN, Melnichenko SV et al. Immunitet u bolnyih saharnyim diabetom 2 tipa s soputstvuyuschim metabolicheskim sindromom/ ozhireniem. Soobschenie 2. Rol adipotsitokinov (interleykina-6, faktora nekrozaopuholey alfa, leptina i adiponektina). Endokrynolohiia. 2013; 18 (2): 26–32. [In Russian] Available from: https://endokrynologia.com.ua/index.php/journal/article/view/387
Suslyk HI. Hiperleptynemiia ta stan insulinovoi rezystentnosti u khvorykh na tsukrovyi diabet 2-ho typu z ozhyrinniam. Klinichna endokrynolohiia ta endokrynna khirurhiia. 2012; 2 (39): 309–16. [In Ukrainian] DOI: https://doi.org/10.24026/1818-1384.2(39).2012.82296
Ott AV, Chumakova GA, Veselovskaya NG. Znachenie leptinorezistentnosti v razvitii razlichnyih metabolicheskih fenotipov ozhireniya. Rossiyskiy kardiologicheskiy zhurnal. 2016; (4): 14–18. [In Russian] Available from: https://russjcardiol.elpub.ru/jour/article/view/676/628
Pereira-Santos M, Costa PR, Assis AM, Santos CA, Santos DB. Obesity and vitamin D
deficiency: a systematic review and meta-analysis. ObesRev. 2015; 16 (4): 341–9. DOI: https://doi.org/10.1111/obr.12239
Fiamenghi VI, Mello ED. Vitamin D deficiency in children and adolescents with obesity: a meta-analysis. J Pediatr (Rio J). 2021; 97 (3): 273–279. DOI: https://doi.org/10.1016/j.jped.2020.08.006
Ding C, Gao D, Wilding J, Trayhurn P, Bing C. Vitamin D signalling in adipose tissue. Br J Nutr. 2012; 108 (11): 1915–1923. DOI: https://doi.org/10.1017/S0007114512003285
Duan L, Han L, Liu Q, Zhao Y, Wang L, Wang Y. Effects of Vitamin D Supplementation on General and Central Obesity: Results from 20 Randomized Controlled Trials Involving Apparently Healthy Populations. Ann NutrMetab. 2020; 76 (3): 153–164. DOI: https://doi.org/10.1159/000507418
Lagunova Z, Porojnicu AC, Lindberg F, Hexeberg S, Moan J. The dependency of vitamin D status on body mass index, gender, age and season. Anticancer Res. 2009; 29 (9): 3713–20. Available from: https://pubmed.ncbi.nlm.nih.gov/19667169/
Vimaleswaran KS, Berry DJ, Lu C et al. Causal Relationship between Obesity and Vitamin D Status: Bi-Directional Mendelian Randomization Analysis of Multiple Cohorts. PLoSMed. 2013. 10(2): 1001383. DOI: https://doi.org/10.1371/journal.pmed.1001383
García-Bailo B, Da Costa LA, Arora P, Karmali M, El-Sohemy A, Badawi A. Plasma vitamin D and biomarkers of cardiometabolic disease risk in adult Canadians, 2007–2009. Prev Chronic Dis. 2013; 10. DOI: https://doi.org/10.5888/pcd10.120230
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682811/
Khan H, Kunutsor S, Franco OH, Chowdhury R. Vitamin D, type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies. Proc Nutr Soc. 2013. 72: 89–97. DOI: https://doi.org/10.1017/S0029665112002765
Huang CY, Chang HH, Lu CW, Tseng FY, Lee LT, Huang KC. Vitamin D status and risk of metabolic syndrome among non-diabetic young adults. Clin Nutr. 2015; 34 (3): 484–9. DOI: https://doi.org/10.1016/j.clnu.2014.05.010
Al-Khalidi B, Kimball SM, Kuk JL, Ardern CI. Metabolically healthy obesity, vitamin D, and all-cause and cardiometabolic mortality risk in NHANES III. Clin Nutr. 2019; 38 (2): 820–828. DOI: https://doi.org/10.1016/j.clnu.2018.02.025
The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
